After celebrating a 1 billion-euro-plus fundraising accomplishment back in March, European venture capital firm Sofinnova Partners is back in the spotlight with the close of another flagship fund.< | ...

Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & ...

Applied Therapeutics’ lack of progress on govorestat as well as the potential costs to come have led analysts to question ...

After dropping so-so early-stage results on its dual GLP-1/GLP-2 agonist earlier this year, fierce competition in the obesity ...

AbbVie is ending an eleven-year agreement with Alphabet’s Calico Labs, according to an internal email obtained by Stat News.

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

After forming from a merger hashed out over plates of tacos about a year ago, nChroma Bio is laying off staff and ...

Bristol Myers Squibb and Johnson & Johnson have stopped a phase 3 anticoagulant trial early for futility, closing off one avenue to market for a molecule tipped to generate multibillion-dollar sales.

Third Arc Bio is paying $5 million upfront to use Adagene’s tech in hopes of creating two new masked T-cell engagers. | Third ...

European life sciences investor Medicxi has raised 500 million euros (about $581.6 million) to go directly toward innovative ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory ...